136 related articles for article (PubMed ID: 33460771)
1. Effect of the ammonium salt anion on the structure of doxorubicin complex and PEGylated liposomal doxorubicin nanodrugs.
Schilt Y; Berman T; Wei X; Nativ-Roth E; Barenholz Y; Raviv U
Biochim Biophys Acta Gen Subj; 2021 May; 1865(5):129849. PubMed ID: 33460771
[TBL] [Abstract][Full Text] [Related]
2. Using solution X-ray scattering to determine the high-resolution structure and morphology of PEGylated liposomal doxorubicin nanodrugs.
Schilt Y; Berman T; Wei X; Barenholz Y; Raviv U
Biochim Biophys Acta; 2016 Jan; 1860(1 Pt A):108-19. PubMed ID: 26391840
[TBL] [Abstract][Full Text] [Related]
3. Cardinal Role of Intraliposome Doxorubicin-Sulfate Nanorod Crystal in Doxil Properties and Performance.
Wei X; Shamrakov D; Nudelman S; Peretz-Damari S; Nativ-Roth E; Regev O; Barenholz Y
ACS Omega; 2018 Mar; 3(3):2508-2517. PubMed ID: 30023837
[TBL] [Abstract][Full Text] [Related]
4. Insights into composition/structure/function relationships of Doxil® gained from "high-sensitivity" differential scanning calorimetry.
Wei X; Cohen R; Barenholz Y
Eur J Pharm Biopharm; 2016 Jul; 104():260-70. PubMed ID: 27106607
[TBL] [Abstract][Full Text] [Related]
5. Rapid scale-up and production of active-loaded PEGylated liposomes.
Roces CB; Port EC; Daskalakis NN; Watts JA; Aylott JW; Halbert GW; Perrie Y
Int J Pharm; 2020 Aug; 586():119566. PubMed ID: 32622812
[TBL] [Abstract][Full Text] [Related]
6. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
7. Investigation of factors affecting in vitro doxorubicin release from PEGylated liposomal doxorubicin for the development of in vitro release testing conditions.
Shibata H; Izutsu K; Yomota C; Okuda H; Goda Y
Drug Dev Ind Pharm; 2015; 41(8):1376-86. PubMed ID: 25170659
[TBL] [Abstract][Full Text] [Related]
8. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
Charrois GJ; Allen TM
Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
[TBL] [Abstract][Full Text] [Related]
9. Size Determination of a Liposomal Drug by Small-Angle X-ray Scattering Using Continuous Contrast Variation.
Garcia-Diez R; Gollwitzer C; Krumrey M; Varga Z
Langmuir; 2016 Jan; 32(3):772-8. PubMed ID: 26673729
[TBL] [Abstract][Full Text] [Related]
10. A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).
Charalambous A; Tsitsi T; Astras G; Paikousis L; Filippou E
Eur J Oncol Nurs; 2021 Feb; 50():101866. PubMed ID: 33227569
[TBL] [Abstract][Full Text] [Related]
11. Effect of the concentration process on unloaded and doxorubicin loaded liposomal dispersions.
Perinelli DR; Cespi M; Rendina F; Bonacucina G; Palmieri GF
Int J Pharm; 2019 Apr; 560():385-393. PubMed ID: 30802548
[TBL] [Abstract][Full Text] [Related]
12. Heating treatments affect the thermal behaviour of doxorubicin loaded in PEGylated liposomes.
Perinelli DR; Cespi M; Bonacucina G; Rendina F; Palmieri GF
Int J Pharm; 2017 Dec; 534(1-2):81-88. PubMed ID: 28993166
[TBL] [Abstract][Full Text] [Related]
13. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
[TBL] [Abstract][Full Text] [Related]
14. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
15. Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer.
Giovinazzo H; Kumar P; Sheikh A; Brooks KM; Ivanovic M; Walsh M; Caron WP; Kowalsky RJ; Song G; Whitlow A; Clarke-Pearson DL; Brewster WR; Van Le L; Zamboni BA; Bae-Jump V; Gehrig PA; Zamboni WC
Cancer Chemother Pharmacol; 2016 Mar; 77(3):565-73. PubMed ID: 26822231
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo characterizations of PEGylated liposomal doxorubicin.
Jiang W; Lionberger R; Yu LX
Bioanalysis; 2011 Feb; 3(3):333-44. PubMed ID: 21320053
[TBL] [Abstract][Full Text] [Related]
17. Pegylated liposomal doxorubicin in ovarian cancer.
Green AE; Rose PG
Int J Nanomedicine; 2006; 1(3):229-39. PubMed ID: 17717964
[TBL] [Abstract][Full Text] [Related]
18. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
19. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08).
Templeton AJ; Ribi K; Surber C; Sun H; Hsu Schmitz SF; Beyeler M; Dietrich D; Borner M; Winkler A; Müller A; von Rohr L; Winterhalder RC; Rochlitz C; von Moos R; Zaman K; Thürlimann BJ; Ruhstaller T;
Breast; 2014 Jun; 23(3):244-9. PubMed ID: 24656636
[TBL] [Abstract][Full Text] [Related]
20. A simple and rapid measurement method of encapsulation efficiency of doxorubicin loaded liposomes by direct injection of the liposomal suspension to liquid chromatography.
Yamamoto E; Miyazaki S; Aoyama C; Kato M
Int J Pharm; 2018 Jan; 536(1):21-28. PubMed ID: 29175642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
